EBO

Medications offered

As listed on the provider’s own site. Whether a product is FDA-approved or compounded is the single most important distinction here — we explain why.

• SemaglutideType not stated

What they publish

EBO publishes 1 of 12 standard terms. Fields marked “not publicly disclosed” were not stated on the pages we captured, and we have not filled those gaps with assumptions. Compare disclosure across providers

Membership / programme fee

Pricing was not published on the page we captured

Medication cost

Not publicly disclosed on the pages we captured.

Introductory offer

Not publicly disclosed on the pages we captured.

Insurance

Not publicly disclosed on the pages we captured.

HSA / FSA

Not publicly disclosed on the pages we captured.

Consultation process

Not publicly disclosed on the pages we captured.

Eligibility

Missouri-oriented service.

Lab work

Not publicly disclosed on the pages we captured.

Pharmacy fulfilment

Not publicly disclosed on the pages we captured.

Shipping

Not publicly disclosed on the pages we captured.

Support services

Not publicly disclosed on the pages we captured.

Cancellation

Not publicly disclosed on the pages we captured.

Refunds

Not publicly disclosed on the pages we captured.

What stands out

• Positioned explicitly around brand-name scarcity, a framing that was more accurate during the shortage period than it is now that the FDA has declared those shortages resolved.
• The page did not state whether the semaglutide supplied is FDA-approved or compounded — which matters more now that the shortage basis for compounding has ended.
• No pricing published.

Questions to ask before you pay

These are things we could not settle from published pages, or that we think are easy to misread. Get answers in writing.

• Ask directly whether the semaglutide is FDA-approved or compounded, and on what legal basis it is compounded if so.
• Establish the monthly cost before starting.